Zacheriah Alexander, MD
Family Medicine · Newton, IANPI 1679525521
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 447 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 21.4% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 447 payments — averaging $12.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$1K
- GSK$470
- AbbVie$449
- Boehringer Ingelheim$334
- Astellas Pharma US Inc$310
- Novo Nordisk$308
- plus $2K from 32 others
Across 1 payment — averaging $2149.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$2K
What the payments were for
- Food & beverage$5,542100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VOQUEZNA$125
How this compares
$5,542 in reported general payments places this provider in the 95th percentile of 1,357 family medicine providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 164 | $197,560 |
| EliquisApixaban | 210 | $146,302 |
| JardianceEmpagliflozin | 139 | $93,586 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 100 | $78,770 |
| TrulicityDulaglutide | 65 | $77,881 |
| MyrbetriqMirabegron | 64 | $45,466 |
| Tresiba Flextouch U-100Insulin Degludec | 48 | $39,528 |
| JanuviaSitagliptin Phosphate | 42 | $37,135 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 74 | $36,534 |
| XareltoRivaroxaban | 43 | $30,653 |
| Tresiba Flextouch U-200Insulin Degludec | 36 | $21,689 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 47 | $21,344 |
| Bydureon BciseExenatide Microspheres | 21 | $17,120 |
| MounjaroTirzepatide | 14 | $14,876 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $14,131 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $308 | $197,560164 claims |
| PfizerEliquis | $1,186 | $146,302210 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $470 | $142,909237 claims |
| Boehringer IngelheimJardiance | $334 | $93,586139 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $264 | $92,75779 claims |
| Astellas Pharma US IncMyrbetriq | $310 | $45,46664 claims |
| MerckJanuvia | $76 | $37,13542 claims |
| Johnson & JohnsonXarelto | $263 | $30,65343 claims |
| AstraZenecaFarxiga, Brilinta | $269 | $14,54335 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $280 | $7,62911 claims |
| AbbVieNamzaric | $449 | $4,71416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,357 family medicine providers in Iowa.
Other family medicine in Newton
- Min PakNewton$11K
- Mureema SolbergNewton$9K
- Steven HillNewton$9K
- Andrew CopeNewton$9K
- Patrick EdwardsNewton$9K
- Kirk PetersonHuxley$576K
- Nicholas GoetschWaterloo$525K
- Stephen HarrisonClinton$249K
- Thomas RossDes Moines$170K
- Yogesh ShahDes Moines$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.